出品 | 创业最前线作者 | 张珏编辑 | 蛋总美编 | 邢静审核 | 颂文随着国内传统药企创新转型步入深水区,药企分拆业务板块独立上市正成为普遍趋势。继去年四环医药拆分轩竹生物、三生制药拆分蔓迪国际等,又一家老牌药企宣布拆分。2026年1月,先声药业旗下的肿瘤创新药平台先声再明正式向港交所递交招股说明书,拟在主板独立挂牌上市。这不仅是先声药业自2020年重回港股后的又一重大资本动作,也标志着这家...
Source Link出品 | 创业最前线作者 | 张珏编辑 | 蛋总美编 | 邢静审核 | 颂文随着国内传统药企创新转型步入深水区,药企分拆业务板块独立上市正成为普遍趋势。继去年四环医药拆分轩竹生物、三生制药拆分蔓迪国际等,又一家老牌药企宣布拆分。2026年1月,先声药业旗下的肿瘤创新药平台先声再明正式向港交所递交招股说明书,拟在主板独立挂牌上市。这不仅是先声药业自2020年重回港股后的又一重大资本动作,也标志着这家...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.